# A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine

> **NCT00419783** · PHASE1 · COMPLETED · sponsor: **Faes Farma, S.A.** · enrollment: 30 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** bilastine
- **DRUG:** Bilastine
- **DRUG:** Bilastine & Ketoconazole
- **DRUG:** Moxifloxacin
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00419783
- **Lead sponsor:** Faes Farma, S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-08
- **Primary completion:** 2006-12
- **Final completion:** 2006-12
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2012-04-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00419783

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00419783, "A Randomized, Multiple Dose, Double Blind, 5-way Crossover Study of the Electrocardiographic (ECG) Effects of Bilastine". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT00419783. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*